Barclays PLC Makes New Investment in CureVac (NASDAQ:CVAC)

Barclays PLC acquired a new position in CureVac (NASDAQ:CVAC) during the third quarter, Holdings Channel reports. The institutional investor acquired 22,946 shares of the company’s stock, valued at approximately $67,000.

Several other hedge funds have also recently added to or reduced their stakes in CVAC. Point72 Asset Management L.P. acquired a new position in shares of CureVac in the second quarter valued at $8,237,000. Public Employees Retirement System of Ohio acquired a new position in shares of CureVac in the 3rd quarter valued at $91,000. China Universal Asset Management Co. Ltd. boosted its position in shares of CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock valued at $127,000 after acquiring an additional 16,792 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in CureVac by 99.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock valued at $147,000 after acquiring an additional 21,999 shares during the period. Finally, Signaturefd LLC raised its position in CureVac by 26.9% in the third quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock worth $82,000 after purchasing an additional 5,927 shares in the last quarter. Institutional investors own 17.26% of the company’s stock.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a report on Monday, September 16th.

CureVac Stock Performance

CureVac stock opened at $4.23 on Friday. CureVac has a 52-week low of $2.21 and a 52-week high of $5.28. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a fifty day moving average price of $3.06 and a two-hundred day moving average price of $3.14. The firm has a market capitalization of $947.01 million, a P/E ratio of 7.69, a P/E/G ratio of 0.24 and a beta of 2.50.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.